Alterity Therapeutics Ltd. (PBN0)
XSTU 
Summary
PBN0 Chart
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
– Clinically Meaningful Efficacy Observed on Multiple Assessments – – Confirmed Target Engagement with Reduced Iron Signal in MSA Affected Brain Regions – MELBOURNE, Australia and SAN FRANCISCO, April 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that new presentations related to its Multiple System Atrophy (MSA) program were delivered at the American Academy of Neurology (AAN) 2025 Annual Meeting, one of the premier global neurology meetings. Notably, new data from the ATH434-201 trial was prominently featured via an oral presentation during a Scientific Platform Session on Movement Disorders.
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
– ATH434 is a Disease Modifying Drug Candidate Targeting Parkinsonian Disorders – – Topline Data Expected Mid-Year 2025 – MELBOURNE, Australia and SAN FRANCISCO, March 27, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that the last patient in the ATH434-202 Phase 2 trial has completed the study. The ATH434-202 is an open label study designed to evaluate the safety, efficacy and target engagement of ATH434 in participants with advanced multiple system atrophy (MSA).
Alterity Therapeutics Raises A$40.0 million in Placement
– Funds to be used primarily to advance development of ATH434 in Parkinsonian Disorders – – Capital raising was strongly supported by domestic and international institutional investors – MELBOURNE, Australia and SAN FRANCISCO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or the “Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced it has received binding commitments for a capital raising of A$40.0 million via a two tranche placement (the “Placement”) of fully paid ordinary shares (“New Shares”) to Australian and international institutions and other unrelated sophisticated, professional or exempt investors. "We are grateful for the strong response from the investment community and are proud to welcome a number of leading domestic and international institutions as shareholders in support of Alterity as we advance our lead compound ATH434 for the treatment of neurodegenerative diseases,” said David Stamler, M.D.
Alterity Therapeutics Ltd. Dividends
Alterity Therapeutics Ltd. Earnings
| 4 Aug 2025 (57 Days) Date | | - Cons. EPS | - EPS |
| 29 Aug 2024 Date | | - Cons. EPS | - EPS |
| 28 Aug 2024 Date | | - Cons. EPS | - EPS |
| 20 Aug 2024 Date | | - Cons. EPS | - EPS |
| 30 Apr 2024 Date | | - Cons. EPS | - EPS |
| 4 Aug 2025 (57 Days) Date | | - Cons. EPS | - EPS |
| 29 Aug 2024 Date | | - Cons. EPS | - EPS |
| 28 Aug 2024 Date | | - Cons. EPS | - EPS |
| 20 Aug 2024 Date | | - Cons. EPS | - EPS |
| 30 Apr 2024 Date | | - Cons. EPS | - EPS |
Alterity Therapeutics Ltd. (PBN0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Alterity Therapeutics Ltd. ever had a stock split?
Alterity Therapeutics Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Dr. David A. Stamler M.D. CEO | XSTU Exchange | US02155X2053 ISIN |
| AU Country | 10 Employees | - Last Dividend | 9 Jan 2023 Last Split | 5 Sep 2002 IPO Date |
Overview
Alterity Therapeutics Limited is a pioneering company focused on the development of novel therapeutics for the treatment of neurodegenerative diseases, including Alzheimer's disease, Huntington's disease, Parkinson's disease, and other neurological disorders. The company, which has been operational since 1997, is located in Melbourne, Australia. Initially known as Prana Biotechnology Limited, it underwent a rebranding to Alterity Therapeutics Limited in April 2019. With its commitment to innovation in the field of neurological disorders, Alterity Therapeutics is at the forefront of research and development efforts to provide new treatment options for these challenging conditions.
Products and Services
- ATH434
ATH434 is Alterity Therapeutics' leading drug candidate currently in Phase I clinical trial, targeting the treatment of Parkinson's disease. This innovative therapeutic approach aims to offer a novel solution for managing and potentially altering the course of Parkinson's disease, shedding hope for those affected by this debilitating condition.
- ATH434-201
This derivative of ATH434 is in Phase II clinical trial, specifically designed to treat multiple system atrophy at an early stage. ATH434-201 represents a strategic expansion of the company's portfolio into addressing more specific neurodegenerative disorders within the spectrum of Parkinsonian syndromes.
- ATH434-202
Similar to ATH434-201 but focused on the advance stage of multiple system atrophy, ATH434-202 is also in Phase II clinical trial. This development underscores Alterity Therapeutics' dedication to providing treatments across different stages of neurodegenerative diseases, catering to a broader patient population.
- PBT2
Having completed a Phase 2a clinical trial, PBT2 addresses Alzheimer's disease, offering a potential treatment option for this profoundly impactful neurodegenerative condition. The completion of this trial stage marks a significant milestone in the quest for Alzheimer's disease therapies, indicating the company's ongoing commitment to groundbreaking research in neurological health.
Contact Information
